
xx Gift of $xx
xx Gift of $xx
Or enter your own donation amount
Please complete your details
* Indicates a required field
xx Gift of $xx
xx Gift of $xx
Or enter your own donation amount
Please complete your details
* Indicates a required field
Listen to our Autumn 2025 Vision Voice online, or order the CD.
Read the Autumn 2025 edition of the Vision Voice newsletter.
Welcome to the latest edition of Vision Voice.
Macular Disease Foundation Australia (MDFA) has welcomed the Federal Government’s decision to defer the private health insurance reclassification of intravitreal (eye) injections from 1 July 2025 to 1 July 2026 and undertake further consultation.
By The Hon. Jillian Skinner, AM, former NSW Minister for Health.This article was originally published by News Corp.
Macular Disease Foundation Australia calls on the next Federal Government to bulk-bill sight-saving eye injections for pensioners; with the potential for creating a $140 million cost-saving per year.
We have released new research in collaboration with the University of New South Wales which has revealed the median total cost for people living with macular disease, who also receive sight-saving eye injections, is 12 percent* ($3,621) of the annual government pension payment.
The Therapeutic Goods Administration (TGA) approval of the new eye injection treatment SYFOVRE® (pegcetacoplan) is welcome news, as it will give many people with Geographic Atrophy a treatment option that they’ve never had before to slow the progression of the disease.
This is our annual research focused edition. In it you will find information about new macular disease treatments, geographic atrophy and innovations being explored to treat, preserve or improve sight.
Our Vision Voice newsletter comes out three times a year. It will keep you up
Macular Disease Foundation Australia (MDFA) has launched its new Research Impact Report, which showcases the groundbreaking projects our organisation has funded to help reduce the impact of macular disease.
We’ve compiled two packs filled with our most popular, evidence-based, macular related resources for your patients.